INFINITE BOOST: FDA advisory panel to consider Johnson & Johnson COVID-19 booster dose.
Poor J&J. Any other time this vaccine would have been a world-beating triumph, but this time it’s been an also-ran, and now it’s losing its major selling point, one-and-done dosing.